IBRX 8-K 2026-10-14

ImmunityBio, Inc. (IBRX) 8-K dated 2026-10-14 — accession 0001193125-26-421820. This URL is the filing, not the IBRX hub.

ImmunityBio, Inc. (IBRX) is a biotechnology company listed on US.

ImmunityBio, Inc. filed a 8-K on 2026-10-14. Accession 0001193125-26-421820.

Cached items: 7.01, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.

Not investment advice. The IBRX SEC hub lists recent forms. The stock page is the research view.